Expression of the SART3 antigens in oral cancers.
It was previously reported that SART3 is a tumor-rejection antigen recognized by HLA-A24-restricted cytotoxic T lymphocytes (CTLs). This study investigated expression of the SART3 antigen in oral cancer as a candidate of tumor antigens for use in specific immunotherapy. The SART3 antigen was detected in all of the oral cancer cell lines tested, 24 of 31 (77%) oral cancer tissue samples, 0 of 3 oral benign tumors and 0 of 3 normal oral tissues. Oral cancer cell lines had the ability to stimulate IFN-gamma production by the HLA-A24-restricted and SART3-specific CTLs that were established from the peripheral blood mononuclear cells (PBMCs) of an esophageal cancer patient. Therefore, the SART3 antigen could be an appropriate vaccine candidate for a large number of oral cancer patients.
Fukuda
K
K
Department of Oral Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D015234:HLA-A Antigens / Q000032:analysis; D059871:HLA-A24 Antigen; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D009062:Mouth Neoplasms / Q000276:immunology* / Q000628:therapy; D016601:RNA-Binding Proteins / Q000032:analysis* / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D016601:RNA-Binding Proteins; C416530:SART3 protein, human; D007371:Interferon-gamma